## **REMARKS**

5

Applicant respectfully requests reconsideration. Claims 21-23, 25, 27-29, 43 and 44 were previously pending in this application. By this amendment, Applicant is canceling claims 25 and 27-29 without prejudice or disclaimer. Claims 21, 43 and 44 have been amended. New claims 45-57 have been added. Support for the claim amendments and newly added claims can be found throughout the specification (See, e.g., pages 2, 4, 7, 8, 23 and 31) and in the claims as originally filed. As a result, claims 21-23 and 43-57 are pending for examination with claim 21 being an independent claim.

No new matter has been added.

## Claim Objections

The Examiner objected to claim 44 as being dependent upon a cancelled base claim. Applicant has amended claim 44 such that it is dependent from claim 21.

Accordingly, it is believed that this objection is now moot.

## Rejection Under 35 U.S.C. §103

Claims 21-23, 25, 27-29 and 43 (Applicant believes the Examiner mistakenly included claims 24 and 30 in the listing of claims for this rejection in the Office Action) are rejected under 35 U.S.C. §103(a) as allegedly being unpatentable over U.S. Patent No. 5,981,714 to Cheng et al., in view of U.S. Patent Nos. 5,955,270 to Radford et al., 5,719,269 to Schwartz et al., 6,329,209 to Wagner et al., 5,750,172 to Meade et al. and Nuijens et al. JBC, 1997, 272(13):8802-7. According to the Examiner, it would have been obvious to develop a method of purifying a target polypeptide either from the milk of a transgenic mammal or mixtures by contacting the target polypeptide with a transgenically produced multivalent binding polypeptide, having a first bindable epitope which binds the target polypeptide and a second bindable epitope which binds a matrix.

Applicant respectfully traverses. However, without conceding the correctness of the Examiner's rejection, Applicant has canceled claims 25 and 27-29. Therefore, the invention as currently claimed relates to a method of obtaining a target polypeptide comprising the step of coexpressing a target polypeptide and a multivalent binding polypeptide in a product of a non-human transgenic mammal. Applicant notes that the Examiner has failed to adequately establish obviousness of the amended claims. None of the references cited by the Examiner, alone or in combination, teach or suggest the step of co-expression of both a target polypeptide and a multivalent binding polypeptide in a product of a non-human transgenic animal. Therefore, even if *arguendo*, one of ordinary skill in the art were to combine the teachings of the cited references, which Applicant does not concede is the case, the methods of the amended claims would not be the result.

6

Accordingly, withdrawal of this rejection is respectfully requested.

## **CONCLUSION**

A Notice of Allowance is respectfully requested. The Examiner is requested to call the undersigned at the telephone number listed below if this communication does not place the case in condition for allowance.

If this response is not considered timely filed and if a request for an extension of time is otherwise absent, Applicants hereby request any necessary extension of time. If there is a fee occasioned by this response, including an extension fee, that is not covered by an enclosed check, please charge any deficiency to Deposit Account No. 23/2825.

Dated: August 28, 2007

Respectfully submitted,

Janice A. Vatland, Ph.D. Registration No.: 52,318

WOLF, GREENFIELD & SACKS, P.C.

Federal Reserve Plaza 600 Atlantic Avenue

Boston, Massachusetts 02210-2206

(617) 646-8000